These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1024 related items for PubMed ID: 24275310

  • 1. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z.
    Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, Nazir J, Chapple C.
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [Abstract] [Full Text] [Related]

  • 3. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E.
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [Abstract] [Full Text] [Related]

  • 4. Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.
    Angulo JC, Khullar V, Nitti VW, Siddiqui E.
    Actas Urol Esp; 2013 Jan; 37(10):640-51. PubMed ID: 23850394
    [Abstract] [Full Text] [Related]

  • 5. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A.
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J, Maman K, Neine ME, Briquet B, Odeyemi IA, Hakimi Z, Garnham A, Aballéa S.
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [Abstract] [Full Text] [Related]

  • 7. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL, Chen TC, Chang HM, Juan YS, Huang WH, Pan HF, Chang YC, Wu CM, Wang YL, Lee HY.
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [Abstract] [Full Text] [Related]

  • 8. Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.
    Lozano-Ortega G, Walker DR, Johnston K, Mickle A, Harrigan S, Rogula B, Kristy RM, Hairston JC, Schermer CR.
    Drugs Aging; 2020 Nov; 37(11):801-816. PubMed ID: 32960422
    [Abstract] [Full Text] [Related]

  • 9. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A.
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [Abstract] [Full Text] [Related]

  • 10. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB.
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [Abstract] [Full Text] [Related]

  • 11. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC.
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C, Chapple C, Mueller ER, Robinson D, Rolland C, Staskin D, Stoelzel M, Maanen RV, Siddiqui E.
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [Abstract] [Full Text] [Related]

  • 13. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
    Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T.
    Curr Med Res Opin; 2016 Dec; 32(4):621-38. PubMed ID: 26828974
    [Abstract] [Full Text] [Related]

  • 14. Mirabegron: A Review in Overactive Bladder Syndrome.
    Deeks ED.
    Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
    Nazir J, Kelleher C, Aballéa S, Maman K, Hakimi Z, Mankowski C, Odeyemi I.
    Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
    [Abstract] [Full Text] [Related]

  • 16. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D, Thiagamoorthy G, Cardozo L.
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [Abstract] [Full Text] [Related]

  • 17. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
    Chapple CR, Siddiqui E.
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Robinson D.
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [Abstract] [Full Text] [Related]

  • 19. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M, Nukui A, Kamai T.
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [Abstract] [Full Text] [Related]

  • 20. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
    Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N.
    Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.